L'Oreal adapts beauty and skincare products to address side effects of GLP-1 weight loss drugs

L'Oreal stated that the rise of GLP-1 weight loss drugs, such as Ozempic, Wegovy, and Mounjaro, is impacting beauty and skincare consumption, prompting the company to design products targeting side effects like loose skin from rapid weight loss. L'Oreal reported a 7.7% rise in sales for the three months to September, exceeding analyst expectations. The company is also increasing its stake in dermatology firm Galderma to 20%, with both companies testing products for GLP-1 users concerned about facial appearance changes.